Orphazyme AS (CHIX:ORPHAC) Days Payable : 0.00 (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Days Payable?

Orphazyme AS's average Accounts Payable for the three months ended in Jun. 2022 was kr26.57 Mil. Orphazyme AS's Cost of Goods Sold for the three months ended in Jun. 2022 was kr0.00 Mil.

The historical rank and industry rank for Orphazyme AS's Days Payable or its related term are showing as below:

CHIX:ORPHAc's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.78
* Ranked among companies with meaningful Days Payable only.

Orphazyme AS's Days Payable stayed the same from Jun. 2020 (0.00) to Jun. 2022 (0.00). stayed the same

Orphazyme AS Days Payable Historical Data

The historical data trend for Orphazyme AS's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Days Payable Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Days Payable

Get a 7-Day Free Trial

Orphazyme AS Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Days Payable	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Orphazyme AS's Days Payable

For the Biotechnology subindustry, Orphazyme AS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orphazyme AS's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orphazyme AS's Days Payable distribution charts can be found below:

* The bar in red indicates where Orphazyme AS's Days Payable falls into.

Orphazyme AS Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Orphazyme AS's Days Payable for the fiscal year that ended in Dec. 2021 is calculated as

	Days Payable (A: Dec. 2021 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2020 )	+	Accounts Payable (A: Dec. 2021 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2021 )	*	Days in Period
=	( (29.937	+	41.78)	/	2 )	/	0	*	365
=	35.8585					/	0	*	365
=	N/A

Orphazyme AS's Days Payable for the quarter that ended in Jun. 2022 is calculated as:

	Days Payable (Q: Jun. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2021 )	+	Accounts Payable (Q: Jun. 2022 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2022 )	*	Days in Period
=	( (41.78	+	11.362)	/	2 )	/	0	*	365 / 4
=	26.571					/	0	*	365 / 4
=	N/A

Orphazyme AS Days Payable Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines